Daily regimen
Dose means the active drug amount. For combination levodopa products, enter the levodopa component only.
| Time | Medication | Dose (mg) | LEDD contribution | Curve | Remove |
|---|
“Days represented” adds prior-day carryover for longer-half-life preparations. Thresholds are optional and user-defined; they are not validated clinical On/Off or dyskinesia cutoffs.
Modeled exposure over 24 hours
Relative normalized exposure index—not a measured plasma concentration or direct prediction of clinical effect.
Use the slider or Left/Right arrow keys for minute-by-minute values. Page Up/Down moves by one hour.
Summary
LEDD is a research comparison measure. The remaining values come from this simplified exposure model and should not guide medication changes.
Save or load a regimen
Exports include a schema version and model version so saved regimens can be interpreted after the model changes.
Medication parameters and sources
LEDD conversion and exposure-curve shape are stored separately. Component curves are normalized so their integrated area matches the declared exposure factor. “Consensus proposal” does not mean clinically validated equivalence for an individual patient.
| Medication | LEDD formula | Exposure model | Evidence/source |
|---|
Not included: the model covers five levodopa preparations (Sinemet, Sinemet CR, Rytary, Crexont, and Inbrija). Other Parkinson medications — levodopa infusions, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and adjuncts — remain outside the graph even when a research LED proposal exists.
Model assumptions and limitations
Exposure shapes. Oral and inhaled doses use a simplified linear rise to a peak followed by exponential elimination. Extended-release products use multiple components. Component areas are normalized to a declared exposure factor.
Important omissions. Absorption lag, protein and meal effects, gastroparesis, renal/hepatic function, endogenous dopamine, drug interactions, rescue-dose context, and person-to-person variability are not modeled. Pharmacokinetics is not pharmacodynamics.
Primary conversion reference. Jost ST et al. Levodopa Dose Equivalency in Parkinson’s Disease: Updated Systematic Review and Proposals. Movement Disorders. 2023.